Trial Profile
A Multi-center Phase II Study Evaluating the Efficacy and Safety of Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor (GIST), Resistent or Intolerant to at Least Imatinib and Sunitinib
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Aug 2020
Price :
$35
*
At a glance
- Drugs Regorafenib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Therapeutic Use
- 07 Aug 2020 Status changed from active, no longer recruiting to completed.
- 08 Mar 2019 Planned End Date changed from 1 Dec 2018 to 1 Dec 2020.
- 01 Feb 2018 Planned End Date changed from 1 Oct 2017 to 1 Dec 2018.